Aniridia Treatment Market Size
Aniridia Treatment Market size was valued at around USD 2.6 billion in 2023 and is estimated to grow at 5.1% CAGR from 2024 to 2032. The market has experienced significant growth due to the increasing prevalence of aniridia.
To get key market trends
Download Free Sample
According to the American Academy of Ophthalmology, the occurrence of aniridia is estimated at around 1.8 per 100,000 live births, with an incidence varying between 1 in 40,000 to 1 in 100,000. Thus, as the awareness and diagnosis of rare diseases are increasing, there is a corresponding rise in demand for effective rare disease treatment options, stimulating research, development (R&D), and investment in therapies tailored to managing this rare genetic disorder.
Aniridia treatment refers to medical interventions aimed at managing and alleviating the symptoms associated with aniridia, a rare genetic disorder characterized by the partial or complete absence of the iris in the eye. Treatment approaches may include supportive medication and surgical procedures to improve vision and manage complications such as glaucoma, cataracts, and other eye disease conditions.
Aniridia Treatment Market Report Attributes
| Report Attribute |
Details |
| Base Year |
2023 |
| Aniridia Treatment Market Size in 2023 |
USD 2.6 Billion |
| Forecast Period |
2024 – 2032 |
| Forecast Period 2024 – 2032 CAGR |
5.1% |
| 2024 – 2032 Value Projection |
USD 4.1 Billion |
| Historical Data for |
2021 – 2023 |
| No. of Pages |
150 |
| Tables, Charts & Figures |
295 |
| Segments covered |
Treatment Type, Type, Age Group, and Region |
| Growth Drivers |
- Rising incidence rate of aniridia
- Increasing awareness for rare diseases
- Growing R&D investment
|
| Pitfalls & Challenges |
- Stringent regulatory requirements
|
What are the growth opportunities in this market?
Download Free Sample
Aniridia Treatment Market Trends
Advances in genetic testing and molecular diagnostics enable healthcare providers to tailor treatment strategies to the specific genetic mutations underlying aniridia caused by a faulty gene (PAX6) in individual patients. This personalized approach enhances treatment efficacy and patient outcomes, driving demand for targeted therapies and contributing to the expansion of the aniridia treatment market.
- For instance, in 2020, Dr. Simpson's project at the University of British Columbia was granted research funding to support the development of a potential gene therapy for the inherited eye disease, aniridia. The study was focused on developing personalized treatment approaches leveraging genetic insights. Also, through advanced genetic testing and molecular analysis, the project aimed to tailor therapies to individual patients, optimizing treatment efficacy and outcomes.
Thus, growing constant support from government along with increasing awareness pertaining to rare disease especially in developed countries will spur the market growth.
Aniridia Treatment Market Analysis
Learn more about the key segments shaping this market
Download Free Sample
Based on treatment type, the market is classified into medication and surgery. The surgery segment is expected to hold the largest market share and maintain dominance to reach USD 3.3 billion by end of 2032.
- The increasing adoption of surgical treatments, coupled with their efficacy in addressing the complex ocular manifestations of aniridia, has propelled this segment to prominence within the market landscape. For instance, HumanOptics offered the CUSTOMFLEX ARTIFICIALIRIS, a distinctive foldable iris prosthesis catering to both medical and aesthetic reconstruction needs in cases of complete or partial aniridia. This innovative solution enhances visual outcomes and addresses the functional and cosmetic aspects associated with aniridia.
- Thus, the growing advancement and treatment options to cater the rare disorders complications aimed to explore opportunities in the market.
Learn more about the key segments shaping this market
Download Free Sample
Based on type, the aniridia treatment market is categorized into congenital aniridia and acquired aniridia. The congenital aniridia segment is projected to hold the largest market share of 88.5% in 2023 and is expected to maintain dominance throughout the analysis period.
- Congenital aniridia is a genetic condition, characterized by the absence or partial absence of the iris from birth, stated challenges that necessitate specialized treatment approaches. Therefore, as congenital aniridia accounted for the majority of cases within the aniridia patient population, there is an increasing emphasis on developing tailored therapies, surgical interventions, and supportive care strategies to address the specific needs of these individuals effectively. Thus, availability of surgery and supportive care options for treating aniridia will spur the market growth.
Based on the age group, the aniridia treatment market is segmented into pediatric and adults. The pediatric segment accounted for the highest share and is expected to reach USD 3.2 billion by end of 2032.
- The dominance of the pediatric segment is attributed to the frequent diagnosis of aniridia during childhood, necessitating early intervention to effectively manage associated ocular complications and improve visual outcomes. Therefore, treatment strategies tailored to pediatric patients, including surgical procedures and pharmacological interventions, are in high demand, thereby driving market dominance in this age group.
Looking for region specific data?
Download Free Sample
North America's aniridia treatment market accounted for the largest revenue and is predicted to witness substantial market growth over the analysis timeline.
- North America has emerged as the dominant force in the market due to several factors such as well-established healthcare infrastructure, advanced technology adoption, and a high prevalence of ocular diseases.
- Also, the presence of key market players and a high level of awareness among healthcare professionals and patients further bolster North America's prominence in the market.
The UK aniridia treatment market is expected to witness high growth over the forecast period.
- UK offers comprehensive healthcare services, including specialized treatment for aniridia. National Health Services (NHS), academic institutions and medical centers collaborate to conduct clinical research and trials to advance treatment options and provide accessibility to the low-income population. Similarly, national healthcare coverage ensures affordability and accessibility to treatments, with a focus on patient-centered care, thereby witnessing market expansion in the country.
The Asia Pacific aniridia treatment market is expected to exhibit the fastest growth over the forecast period.
- The Asia Pacific region is experiencing significant growth in the market due to several factors such as rising healthcare expenditure, increasing awareness about ocular disorders, and a growing patient population are driving demand for advanced treatment options.
- Moreover, government initiatives supporting healthcare infrastructure development and research in the region contribute to market expansion.
- Further, with advancements in ophthalmic surgical techniques, procedures such as keratoplasty, iris reconstruction, and artificial iris implantation offer promising outcomes for managing the visual impairments associated with aniridia. Thus, aforementioned factor is expected to supplement the market growth.
Aniridia Treatment Market Share
The aniridia treatment industry features several key players vying for market share. The companies are focusing on competing based on factors such as product efficacy, pricing strategies, technological advancements, and geographical reach. Additionally, collaborations, partnerships, and acquisitions are common strategies employed to strengthen market presence.
Aniridia Treatment Market Companies
Some of the eminent participants operating in the aniridia treatment industry include
- AbbVie Inc.
- Bausch & Lomb Incorporated
- F. Hoffmann-La Roche Ltd
- HumanOptics AG
- Johnson & Johnson Vision
- MORCHER GmbH
- Novartis AG
- Ophtec
- Pfizer Inc.
- REPER-NN LTD.
Aniridia Treatment Industry News
- In February 2022, VEO Ophthalmics, LLC collaborated with Aniridia Foundation International (AFI) to increase awareness of aniridia and its treatment options. This strategic partnership aims to bolster the customer base and enhance awareness of aniridia and its treatment options.
The aniridia treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments
Click here to Buy Section of this Report
Market, By Treatment Type
- Medication
- Type
- Eye drop
- Ointments
- Other medication types
- Distribution channel
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
- Surgery
- Surgery type
- Keratoplasty
- Artificial iris implantation
- Glaucoma drainage devices
- Trabeculectomy
- Goniotomy
- Other surgery types
- End-user
- Hospitals
- Specialty clinics
- Ambulatory surgical centers
- Other end-users
Market, By Type
- Congenital aniridia
- Isolated aniridia
- WAGR syndrome
- Gillespie syndrome
- Acquired aniridia
Market, By Age Group
The above information is provided for the following regions and countries
- North America
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Netherlands
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East and Africa
- Saudi Arabia
- South Africa
- UAE
- Rest of Middle East and Africa
